Exchange: EURONEXT Sector: Healthcare Industry: Biotechnology
4.05% €8.22
America/New_York / 17 mai 2024 @ 11:12
FUNDAMENTALS | |
---|---|
MarketCap: | 95.49 mill |
EPS: | -1.700 |
P/E: | -4.84 |
Earnings Date: | Apr 02, 2024 |
SharesOutstanding: | 11.62 mill |
Avg Daily Volume: | 0.0023 mill |
RATING 2024-05-17 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | n/a | |||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.84 | sector: PE 17.08 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -4.84 | industry: PE -7.48 |
DISCOUNTED CASH FLOW VALUE |
---|
€-5.00 (-160.82%) €-13.22 |
Date: 2024-05-19 |
Expected Trading Range (DAY) |
---|
€ 7.92 - 8.52 ( +/- 3.61%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | €8.22 (4.05% ) |
Volume | 0.0029 mill |
Avg. Vol. | 0.0023 mill |
% of Avg. Vol | 125.71 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.